Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study-Reference-Cited by-同舟云学术

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

Published:2021-03-18 Issue:5 Volume:39 Page:1298-1305
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Pedersen Katrina S.^ORCID,Grierson Patrick M.,Picus Joel,Lockhart A. Craig,Roth Bruce J.,Liu Jingxia,Morton Ashley,Chan Emily,Huffman Jesse,Liang Chris,Wang-Gillam Andrea,Tan Benjamin

Funder

Xcovery

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-021-01093-7.pdf

Reference19 articles.

1. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473–1482. https://doi.org/10.1016/S1470-2045(15)00290-9

2. Cohen MM Jr (2009) Judah Folkman, MD, 1933-2008: father of angiogenesis. J Craniofac Surg 20(Suppl 1):590–591. https://doi.org/10.1097/SCS.0b013e3181927e8a

3. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1(2):193–202

4. Hansel DE, Rahman A, Hermans J, de Krijger RR, Ashfaq R, Yeo CJ, Cameron JL, Maitra A (2003) Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 16(7):652–659. https://doi.org/10.1097/01.MP.0000077416.68489.50

5. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299–309. https://doi.org/10.1016/j.ccr.2005.09.005

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Visible light–driven organic synthesis under other miscellaneous photocatalysis;Visible Light-Driven Organic Synthesis;2025

2. Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration;Ophthalmology Science;2024-09

3. CM082 suppresses hypoxia-induced retinal neovascularization in larval zebrafish;Frontiers in Pharmacology;2024-07-29

4. Adverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-06-26

5. New modified thieno[2,3-d]pyrimidine derivatives as VEGFR-2 inhibitors: Design, synthesis, in vitro anti-cancer evaluation and divers in silico studies;Journal of Molecular Structure;2024-04